Cellromax Science Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Operating Revenue	19,604	22,184	21,630
Other Revenue	-	-	-0
Revenue	19,604	22,184	21,630
Revenue Growth	-16.01%	2.56%	-
Cost of Revenue	9,790	11,637	9,346
Gross Profit	9,814	10,547	12,284
Selling, General & Admin	7,052	7,100	6,228
Amortization of Goodwill & Intangibles	10.7	4.02	1.67
Other Operating Expenses	160.39	133.87	112.08
Operating Expenses	7,661	7,712	6,784
Operating Income	2,153	2,835	5,501
Interest Expense	-24.85	-50.49	-37.78
Interest & Investment Income	505.88	780.22	1,376
Currency Exchange Gain (Loss)	-3.22	-4.8	-2.83
Other Non Operating Income (Expenses)	-4.4	-247.81	-1,783
EBT Excluding Unusual Items	2,626	3,313	5,052
Gain (Loss) on Sale of Investments	114.59	127.93	71.81
Gain (Loss) on Sale of Assets	4.38	10.82	11.85
Pretax Income	2,745	3,451	5,136
Income Tax Expense	-322.45	484.82	1,319
Net Income	3,068	2,966	3,817
Net Income to Common	3,068	2,966	3,817
Net Income Growth	45.17%	-22.29%	-
Shares Outstanding (Basic)	11	11	10
Shares Outstanding (Diluted)	11	11	10
Shares Change	2.94%	9.70%	-
EPS (Basic)	273.95	264.20	367.00
EPS (Diluted)	273.02	261.00	367.00
EPS Growth	41.33%	-28.88%	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	2,126	1,707	6,088
Free Cash Flow Per Share	188.50	149.58	585.32
Gross Margin	50.06%	47.54%	56.79%
Operating Margin	10.98%	12.78%	25.43%
Profit Margin	15.65%	13.37%	17.65%
Free Cash Flow Margin	10.84%	7.69%	28.15%
EBITDA	2,602	3,314	5,936
EBITDA Margin	13.27%	14.94%	27.44%
D&A For EBITDA	448.96	478.45	435.41
EBIT	2,153	2,835	5,501
EBIT Margin	10.98%	12.78%	25.43%
Effective Tax Rate	-	14.05%	25.68%
Advertising Expenses	-	639.1	484.04